News Headlines Article

Blocking pay-for-delay deals a priority for FTC
Modern Healthcare

Bolstered by a high-profile legal victory at the U.S. Supreme Court this spring, the Federal Trade Commission has made the blocking of “pay-for-delay” settlements by drug companies one of its highest priorities—even reviewing older settlements to see if retroactive enforcement is possible, according to congressional testimony Tuesday. The FTC opposes the increasing number of legal deals in which the makers of high-priced branded drugs pay settlements to generic manufacturers to delay the flood of cheaper generics that typically drives down drug prices by 85% after patents expire.